Clene outlines 2026 regulatory milestones and ALS strategy

An announcement from Clene ( (CLNN) ) is now available.

On February 24, 2026, Clene issued a letter to stockholders outlining key regulatory and clinical milestones it expects for CNM-Au8 in 2026, anchored by an operating cash runway projected into the fourth quarter of 2026 after a January capital raise. The company said its financing structure, tied to potential regulatory milestones, is expected to support operations through a prospective FDA decision on an accelerated approval, with additional capital potentially extending into 2027.

Clene detailed that an in-person Type C meeting with the FDA’s neurology division is scheduled by the end of the first quarter of 2026 to review extensive CNM-Au8 data submitted in late 2025. Contingent on this interaction, the company plans to file a New Drug Application via an accelerated pathway in the second quarter of 2026, targeting possible FDA acceptance and a PDUFA decision date in the second half of 2026 and positioning for a potential commercial launch in 2027.

Management highlighted clinical findings from multiple Phase 2 trials and open-label extensions in ALS, reporting prolonged survival, slowed clinical worsening, and statistically significant reductions in neurofilament light chain and GFAP biomarkers associated with neurodegeneration. Clene argues that these data, along with regulatory precedent for using NfL as a surrogate endpoint, support CNM-Au8’s candidacy for accelerated approval and strengthen the company’s negotiating stance with regulators.

The company also emphasized CNM-Au8’s safety profile, citing more than 1,000 patient-years of exposure with predominantly mild-to-moderate adverse events, no drug-related serious adverse events, and no long-term safety signals observed. Clene contends that this benign tolerability could bolster the therapy’s benefit–risk assessment in ALS, a setting where unmet need remains high and previous drugs with favorable safety have secured accelerated approvals based on Phase 2 data.

To satisfy confirmatory requirements for accelerated approval and reinforce the observed survival benefit, Clene plans to initiate dosing in its Phase 3 RESTORE-ALS trial later in 2026. The double-blind, placebo-controlled study, whose design has already been reviewed with the FDA, is intended to evaluate CNM-Au8’s impact on survival and clinical worsening events, adding pivotal-scale evidence that could shape its long-term commercial profile.

Beyond ALS, Clene noted that CNM-Au8 has shown promising signals in multiple sclerosis and Parkinson’s disease and that it expects to finalize a Phase 3 MS trial design focused on cognition in 2026 following FDA feedback. These pipeline plans suggest the company is preparing to leverage any regulatory traction in ALS to expand CNM-Au8’s addressable market, potentially enhancing its future revenue prospects and strategic positioning in neurodegenerative therapeutics.

The most recent analyst rating on (CLNN) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Spark’s Take on CLNN Stock

According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.

The score is held down primarily by very weak financial performance (minimal and declining revenue, large ongoing losses, negative equity and continued cash burn). Technicals also reflect a bearish trend with weak momentum. Offsetting factors include positive corporate developments (financing that extends runway and FDA engagement around biomarker-driven regulatory strategy), but they do not yet resolve the underlying financial risk.

To see Spark’s full report on CLNN stock, click here.

More about Clene

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. Its lead investigational therapy, CNM-Au8, is an oral gold nanocrystal suspension designed to enhance central nervous system cell survival and function, with operations based in Salt Lake City and manufacturing in Maryland.

The company positions CNM-Au8 as a potential “pipeline-in-a-product,” initially targeting ALS and expanding into multiple sclerosis and Parkinson’s disease to build a broader neurodegenerative portfolio. It aims to leverage a first-in-class mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress, seeking a foothold in high-need neurology markets where few effective treatments exist.

Average Trading Volume: 167,993

Technical Sentiment Signal: Strong Sell

Current Market Cap: $53.24M

See more data about CLNN stock on TipRanks’ Stock Analysis page.